Stability of the latent reservoir for HIV-1 in patients receiving valproic acid

Journal of Infectious Diseases

Volumn 195, Issue 6, 2007, Pages 833-836

  Siliciano, Janet D ^a   Lai, Jun ^a   Callender, Marc ^a   Pitt, Eleanor ^a   Zhang, Hao ^b   Margolick, Joseph B ^b   Gallant, Joel E ^a   Cofrancesco Jr , Joseph ^a   Moore, Richard D ^a   Gange, Stephen J ^b   Siliciano, Robert F ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; CD4 ANTIGEN; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; RITONAVIR; TENOFOVIR; VALPROIC ACID; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG STABILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SHORT COURSE THERAPY; VIREMIA; VIRUS LATENCY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; DISEASE RESERVOIRS; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; VALPROIC ACID; VIRUS REPLICATION;

EID: 33847642822     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/511823     Document Type: Article

References (15)

1. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
2. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-5.
3. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94:13193-7.
4. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-8.
5. Brooks DG, Hamer DH, Arlen PA, et al. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003; 19:413-23.
6. Han Y, Lassen K, Monie D, et al. Resting CD4+ T cells from HIV-1-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 2004; 78:6122-33.
7. Verdin E, Paras P Jr, Van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 1993; 12:3249-59.
8. He G, Margolis DM. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 2002; 22:2965-73.
9. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25:139-49.
10. Peterson GM, Naunton M. Valproate: a simple chemical with so much to offer. J Clin Pharm Ther 2005; 30:417-21.
11. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anti-convulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276:36734-41.
12. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-I from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18:1101-8.
13. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549-55.
14. Laird NM, Ware JH. Random effects models for longitudinal data. Biometrics 1982; 38:963-74.
15. Steel A, Clark S, Teo I, et al. No change to HIV-1 latency with valproate therapy. AIDS 2006; 20:1681-2.